How should varicella (chickenpox) be treated in otherwise healthy children and in high‑risk patients such as those older than 12 years, immunocompromised, pregnant, or with chronic lung or heart disease?

Treatment of Chickenpox

Routine antiviral treatment is NOT recommended for otherwise healthy children with chickenpox, but oral acyclovir should be strongly considered for high-risk patients including those ≥12 years old, immunocompromised individuals, pregnant women, and those with chronic lung or heart disease—initiated within 24 hours of rash onset. 1

Treatment Approach by Patient Population

Otherwise Healthy Children (<12 years)

Do not routinely treat with antivirals. The AAP concluded that acyclovir administration to healthy children lacks sufficient clinical benefit to justify routine use 1. While FDA-approved oral acyclovir reduces fever duration, number of lesions, and symptom severity when given within 24 hours of rash onset, it does NOT:

• Decrease varicella transmission
• Reduce school absence duration
• Significantly reduce complications (only 1-2% complication rate in studies, insufficient to demonstrate statistical benefit) 1

Provide supportive care only: symptom management, hydration, and monitoring for complications.

High-Risk Patients Requiring Antiviral Therapy

Oral acyclovir should be considered for the following groups when administered within 24 hours of rash onset 1:

• Persons ≥12 years old (adolescents and adults have 13-25 times higher hospitalization and death rates) 1
• Chronic cutaneous or pulmonary disorders (including asthma, COPD, chronic heart disease) 1
• Patients on long-term salicylate therapy 1
• Patients receiving short, intermittent, or aerosolized corticosteroids 1
• Secondary household contacts (some experts recommend for household members exposed to infected children) 1

Dosing for oral acyclovir:

• Ages 5-7 years: 20 mg/kg four times daily
• Ages 7-12 years: 15 mg/kg four times daily
• Ages 12-16 years: 10 mg/kg four times daily
• Duration: 5-7 days 2

Immunocompromised Patients

Intravenous acyclovir is mandatory for immunocompromised patients with altered cell-mediated immunity 1, 3. When administered within 24 hours of rash onset, IV acyclovir has been demonstrated to effectively reduce varicella-associated morbidity and mortality in this population 1.

Also use IV acyclovir for:

• Newborns during first 2 weeks of life
• Preterm infants in neonatal nursery
• Children <2 years at risk of dissemination 3

Pregnant Women

Acyclovir is FDA Category B in pregnancy 1. A prospective registry of 596 first-trimester exposures showed birth defect rates approximating the general population 1.

Treatment approach:

• AAP has NOT recommended routine oral acyclovir for pregnant women due to unknown fetal risks/benefits
• However, IV acyclovir SHOULD be considered for serious viral-mediated complications (e.g., pneumonia) 1
• Early antiviral therapy is linked to symptomatic relief and reduced mortality in varicella pneumonia 4

Patients with Chronic Lung or Heart Disease

Strongly consider oral acyclovir within 24 hours of rash onset 1. These patients are at increased risk for:

• Varicella pneumonia (5-15% of adult varicella cases develop pulmonary manifestations) 4, 5
• Exacerbation of underlying cardiopulmonary disease
• Secondary bacterial sepsis 3

Smoking, chronic obstructive pulmonary disease, and chronic lung diseases are established risk factors for severe varicella pneumonia 4, 5.

Critical Timing Considerations

The 24-hour window is non-negotiable. All clinical trials demonstrating acyclovir efficacy required administration within 24 hours of rash onset 1. Beyond this window, clinical benefit is substantially diminished.

Common Pitfalls to Avoid

• Do not use acyclovir prophylactically in otherwise healthy children, adolescents, or adults after varicella exposure—vaccination is the method of choice 1
• Avoid aspirin during varicella due to Reye syndrome risk 1
• Do not delay IV acyclovir in immunocompromised patients waiting for laboratory confirmation
• Remember that antibody titers are preserved with acyclovir treatment—concerns about reduced immunity are unfounded 1

Post-Exposure Prophylaxis for High-Risk Patients

For immunocompromised patients, pregnant women without immunity, and specific neonatal populations exposed to varicella:

VariZIG (varicella zoster immune globulin) should be administered as soon as possible and within 10 days of exposure 6. Dosing: 125 IU/10 kg body weight, maximum 625 IU (five vials) 6.

If VariZIG is unavailable or the window has passed, consider prophylactic acyclovir for immunocompromised persons, though no formal studies support this practice 1.